ロード中...
Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas
PURPOSE: Pembrolizumab, a programmed cell death protein 1 (PD1) inhibitor inhibits the interplay between PD1 of T-cell and programmed cell death ligand 1 (PDL1) on tumor cells. Although pembrolizumab has been tried to various subtypes of non-Hodgkin lymphoma (NHL), real-world data about the efficacy...
保存先:
| 出版年: | Cancer Res Treat |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Korean Cancer Association
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6473267/ https://ncbi.nlm.nih.gov/pubmed/30025443 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2018.191 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|